高樹庚，1966年生，籍貫山東，胸外科專家，腫瘤醫(yī)院副院長，主任醫(yī)師，博士生導(dǎo)師。1984年考入山東醫(yī)科大學(xué)臨床醫(yī)學(xué)專業(yè)，1989年獲得學(xué)士學(xué)位。1995年在中國協(xié)和醫(yī)科大學(xué)腫瘤學(xué)專業(yè)攻讀碩士學(xué)位，從事胸部腫瘤相關(guān)研究。2002年在中國協(xié)和醫(yī)科大學(xué)腫瘤學(xué)專業(yè)攻讀博士學(xué)位，從事胸部腫瘤臨床和轉(zhuǎn)化研究。2011年進(jìn)入北京協(xié)和醫(yī)學(xué)院腫瘤研究所進(jìn)行博士后研究工作，主要從事胸部腫瘤相關(guān)研究。1995年升為主治醫(yī)師。2003年為副主任醫(yī)師，2008年為主任醫(yī)師。

肺癌微創(chuàng)外科治療，早期非小細(xì)胞肺癌術(shù)式的創(chuàng)新及改進(jìn)；局部晚期非小細(xì)胞肺癌新輔助治療模式構(gòu)建；探索基于外周血ctDNA改變?cè)诜伟?fù)發(fā)轉(zhuǎn)移預(yù)測中的應(yīng)用及其相關(guān)機(jī)制，推動(dòng)基礎(chǔ)研究的臨床轉(zhuǎn)化。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Guo W#, Zhou B#, Yang Z#, Liu X, Huai Q, Guo L, Xue X, Tan F, Li Y, Xue Q, Gao S*, He J. Integrating microarray-based spatial transcriptomics and single-cell RNA-sequencing reveals tissue architecture in esophageal squamous cell carcinoma. EBioMedicine. 2022 Oct;84:104281. (IF=11.205)

2. Zhou B#, Bie F#, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhao J*, Gao S*. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer. EBioMedicine. 2022 Oct;84:104268. (IF=11.205)

3. Qiu B#, Ji Y#, Zhang F, Bai G, Xue Q, Polaczek M, Tosi D, Koike T, Gao S*, He J. Outcomes and experience of anatomical partial lobectomy. J Thorac Cardiovasc Surg. 2022 Sep;164(3):637-647.e1. (IF=6.439)

4. Guo W#, Chen X, Liu R, Liang N, Ma Q, Bao H, Xu X, Wu X, Yang S, Shao Y, Tan F, Xue Q, Gao S*, He J. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling. EBioMedicine. 2022 Jul;81:104131. (IF=11.205)

5. Zhang F#, Guo W#, Zhou B#, Wang S, Li N, Qiu B, Lv F, Zhao L, Li J, Shao K, Xue Q, Gao S*, He J. Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2022 Jul;17(7):909-920. (IF=20.121)

6. Zhou B#, Zang R, Zhang M, Song P, Liu L, Bie F, Peng Y, Bai G, Gao S*. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study. EBioMedicine. 2022 Apr;78:103951. (IF=11.205)

7. Wang S#, Yuan P#, Mao B#, Li N, Ying J, Tao X, Tang W, Zhang L, Geng X, Zhang F, Xue Q, Wu L, Zhang H*, Gao S*, He J. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ Precis Oncol. 2022 Jan 13;6(1):2. (IF=10.092)

8. Qiu B#, Guo W#, Zhang F, Lv F, Ji Y, Peng Y, Chen X, Bao H, Xu Y, Shao Y, Tan F, Xue Q, Gao S*, He J. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021 Nov 19;12(1):6770. (IF=17.694)

9. Yang Z#, Xu J, Li L, Li R, Wang Y, Tian Y, Guo W, Wang Z, Tan F, Ying J, Jiao Y, Gao S*, Wang J*, Gao Y*, He J*. Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun. 2020 Sep 28;11(1):4878. (IF=14.919)

10. Gao S#, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, Shao K, Lei W, Wang D, Lv F, Zhao L, Zhang F, Zhao Z, Su K, Tan F, Gao Y, Sun N, Wu D, Yu Y, Ling Y, Wang Z, Duan C, Tang W, Zhang L, He S, Wu N, Wang J, He J*. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020 May;15(5):816-826. (IF=15.609, ESI)